Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.08.15.670586

Free fatty acid receptor 4 agonists stimulate insulin secretion via different mechanisms in mouse versus human islets

Abstract

The free fatty acid receptor FFAR4 is expressed in pancreatic islets, and its activation potentiates insulin and inhibits somatostatin (SST) secretion. We investigated the mechanisms of action of FFAR4 on hormone secretion in mouse and human islets. The effects of the FFAR4 agonist Compound A (Cpd A) on insulin and SST secretion were investigated in islets from mice following ablation of {delta} cells, deletion of SST and deletion of the G protein Gz (Gnaz-/-), in purified mouse {beta} and {delta} cells, in human EndoC-{beta}H5 cells, and in human islets. Ca++ dynamics in response to Cpd A were measured in {delta} cells from Gnaz-/- mouse islets and in human islets. The insulinotropic effect of Cpd A was lost in {delta} cell-ablated and SST-deficient mouse islets and was absent in purified mouse {beta} cells. Gz deletion prevented Cpd A inhibition of SST secretion but not the potentiation of insulin release. Cpd A diminished Ca++ transients in mouse {delta} cells, an effect that was lost in Gz deficient islets. In human islets, FFAR4 activation increased insulin secretion and intracellular Ca++ transient independent of SST secretion. Consistent with a direct effect on {beta} cells, Cpd A potentiated insulin secretion in human EndoC-{beta}H5 cells. We conclude that FFAR4 activation stimulates insulin secretion from mouse islets indirectly via Gz-coupled inhibition of SST secretion from {delta} cells, while in human islets, it stimulates insulin release via a direct effect on {beta} cells. These key species-related differences are to be taken into account as FFAR4 is considered a potential therapeutic target for metabolic diseases. STRUCTURED ABSTRACTO_ST_ABSObjectivesC_ST_ABSThe free fatty acid receptor FFAR4 (GPR120) is expressed in the murine islet where its activation promotes insulin and glucagon and inhibits somatostatin (SST) secretion. However, its precise mechanism of action in different islet cells is still unknown, and potential species-related differences have not been explored. This study was aimed to address three questions: 1-What is the relative importance of {delta} cells and SST in the insulinotropic effect of FFAR4 in mouse islets? 2-Which G protein does FFAR4 couple to in mouse {delta} cells? 3-Does FFAR4 stimulate insulin secretion by similar mechanisms in mouse and human islets? MethodsThe effects of the FFAR4 agonist Compound A (Cpd A) on insulin and SST secretion were investigated in islets from mice following ablation of {delta} cells, deletion of SST and deletion of the G protein Gz (Gnaz-/-), in purified mouse {beta} and {delta} cells, in human EndoC-{beta}H5 cells, and in human islets. Ca++ dynamics in response to Cpd A were measured in {delta} cells from Gnaz-/- mouse islets and in human islets using adenovirally-transduced Ca++ reporters. ResultsThe insulinotropic effect of Cpd A was lost in {delta} cell-ablated and SST-deficient mouse islets and was absent in purified mouse {beta} cells. Gz deletion diminished Ca++ transients in mouse {delta} cells, prevented Cpd A inhibition of SST secretion but did not inhibit the potentiation of insulin release. In human islets, FFAR4 activation increased insulin secretion and intracellular Ca++ transient without affecting SST secretion. Consistent with a direct effect on {beta} cells, Cpd A potentiated insulin secretion in human EndoC-{beta}H5 cells. ConclusionFFAR4 activation stimulates insulin secretion from mouse islets indirectly via Gz-coupled inhibition of SST secretion from {delta} cells, while in human islets, it stimulates insulin release via a direct effect on {beta} cells. These key species-related differences are to be taken into account as FFAR4 is considered a potential therapeutic target for metabolic diseases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Reininger, L., Rehman, M. H., Bouabcha, A., Ferragne, S., Tremblay, C., Ethier, M., Kimple, M. E., Ghislain, J., Huising, M. O., Poitout, V.. 2025-08-18. Free fatty acid receptor 4 agonists stimulate insulin secretion via different mechanisms in mouse versus human islets. https://doi.org/10.1101/2025.08.15.670586

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A dynamic phosphoproteome reveals stage-specific regulation of cytokinesis in Leishmania

Leishmania parasites undergo extensive morphological and metabolic remodelling during their transition from motile insect promastigotes to non-motile intracellular amastigotes, yet how dynamic protein kinase signalling drives this process remains poorly understood. Here, we present a high-resolution temporal phosphoproteome of L. mexicana promastigote to axenic amastigote differentiation, profiling 16,495 phosphosites on 3,101 proteins across seven developmental time points and identifying 5,795 dynamically regulated sites. This temporal map reveals stage-specific signalling programs, including regulated sites in MPK2 and non-regulated sites in MRK1, protein kinases known to be essential for amastigote differentiation. Using analogue-sensitive (AS) chemical genetics, we show that acute inhibition of either kinase in axenic amastigotes disrupts the spatial coordination of cleavage furrow ingression with nuclear and kinetoplast segregation, revealing essential cytokinesis roles obscured in constitutive gene deletions. Despite generating similar cytokinesis phenotypes, genetic over-expression and cellular localisation analyses demonstrate that MPK2 and MRK1 act through spatially segregated signalling pathways. Time-resolved phosphoproteomics upon MPK2 inhibition places its activity upstream of cytoskeletal remodelling networks. Importantly, we show that the stage-specific requirement for MPK2 is defined by the parasite's morphology: while motile promastigotes tolerate MPK2 inhibition, genetic ablation of flagellar motility sensitises them to loss of MPK2 activity. Thus, flagellar motility acts as a mechanical buffer during promastigote division, explaining why non-motile amastigotes are vulnerable to MPK2 inhibition. Together, our findings provide a systems level framework for Leishmania signalling and demonstrate that cellular architecture and biomechanics dictate protein kinase dependency across developmental stages of the parasite.

cell biology↗

Single-cell Transcriptome-Proteome-PTMome(x8)-Metabolome (scTPPM) co-profiling decodes multimodal regulation during mouse oocyte meiosis

Single-cell multi-omics technology is crucial for comprehensive characterization of cellular molecular features. Despite recent advances in single-cell multi-omics approaches, co-profiling of nucleic acids, proteins, metabolites, and post-translational modifications (PTMs) within the same cell individuals remains major challenges. Here, we developed a single-cell transcriptome, proteome, PTMome, and metabolome (scTPPM) profiling approach, enabling simultaneous analysis of transcriptomes, proteomes, eight types of PTMs (e.g., phosphorylation, methylation, ubiquitination, O_GlcNAc, acetylation, crotonylation, lactylation, and succinylation), and metabolomes in individual cells. We demonstrated the scTPPM's performance in tumor cell lines and oocyte samples, reaching total identification and quantification of 27,668 genes, 4,847 proteins, 1,508 PTM sites, and 680 metabolites in single mouse oocytes. We profiled previously-uncharacterized dynamic crosstalk among the entire metabolic pathways from metabolic enzyme expression and regulation to metabolite-mediated post-translational modifications during oocyte maturation. In summary, scTPPM provided an effective workflow for multi-omics co-profiling in single cells, enabling multi-layered insights into complex regulatory network.

cell biology↗

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗